Group 1: Company Overview - The company operates in the fine chemical sector, focusing on the research, production, and sales of surfactants and cleaning products, with production bases in Changsha, Shanghai, and Dongguan [1] - The annual production capacity for surfactants is approximately 550,000 tons, while the capacity for cleaning products is around 250,000 tons [1] Group 2: Financial Performance - In 2024, the company achieved a revenue of CNY 3.377 billion from surfactant products, marking a 12.68% increase compared to the previous year, accounting for 92.23% of total revenue [2] - The company has maintained a dividend payout ratio of 60% over the past three years, with a proposed cash dividend of CNY 5.10 per 10 shares for 2024, totaling CNY 66,390,912.60 [3] Group 3: Shareholder Returns and Incentives - The company has established a three-year shareholder return plan (2024-2026) to ensure stable and reasonable returns for investors [3] - In 2024, the estimated share-based payment expense is CNY 33.17 million, with management expenses accounting for 68.03% and sales expenses for 25.09% [4] Group 4: Project Updates - The Shanghai Aowei 250,000 tons new green surfactant production base has entered trial production as of early May 2024, with full production expected to take some time [5] - The second phase of the Shanghai project includes a production line with an annual capacity of 57,500 tons, which is also in trial production as of early April 2025 [5]

证券代码：000731 证券简称：四川美丰 四川美丰化工股份有限公司 2024 年度及 2025 年一季度业绩说明会投资者活动记录表 编号：20250514 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系 | □媒体采访 √业绩说明会 | | | □新闻发布会 □路演活动 | | 活动类别 | □现场参观 □电话会议 | | | □其他：（请文字说明其他活动内容） | | 参与单位名称 | 四川美丰2024年度及2025年一季度业绩说明会采用网 | | 及人员姓名 | 络远程方式进行，面向全体投资者 | | 时间 | 2025 年 5 月 14 日 15:00～17:00 | | 地点 | "价值在线"网络平台 | | 公司接待 | 董事长、总裁王勇，独立董事朱厚佳，董事会秘书王 | | 人员姓名 | 东，财务总监李全平 | | | 一、本次活动的基本情况 公司于 2025 年 5 月 14 日 15:00～17:00，通过 | | | "价值在线"网络平台举行了 2024 年度及 2025 年一 | | 投资者关系活动 | 季度网上业绩说明会，以线上交流方式回答了投资者 ...

永安行科技股份有限公司 会议文件 （更新版） 为维护全体股东的合法利益，确保本次股东大会能够依法行使职权，根据《中华人民共和 国公司法》 《上市公司股东会规则》及本公司《章程》和《股东大会议事规则》的有关规定，特 制定本次股东大会会议须知，望全体参会人员严格遵守并执行： 一、股东大会召开过程中，参会股东或股东代理人（以下统称"股东"）应当以维护全体股 东的合法权益、确保大会正常秩序和议事效率为原则，认真履行法定职责。 二、参会股东依法享有发言权、质询权、表决权等各项权利。股东应认真履行法定义务， 自觉遵守大会纪律，不得侵犯其他股东的权益，以确保股东大会的正常秩序。 三、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，务请出席大会的股 东及相关人员准时到达会场签到确认参会资格。 四、如股东拟在本次股东大会上发言，应于会议开始前在签到处登记并填写"股东发言登记 表"。股东发言或提问应围绕本次会议议题进行，简明扼要，建议每次发言时间不超过三分钟。 永安行科技股份有限公司 2025 年第一次临时股东 大会会议文件（更新版） 目 录 议案四：关于公司 2025 年度向特定对象发行 A 股股票方案论证分析报告（ ...

鹭燕医药（002788）公告，公司董事会制定了《鹭燕医药股份有限公司未来三年股东回报规划(2025 年-2027年)》。规划中提出，公司将优先采用现金方式分配股利，并在符合分红条件的情况下，每年按 当年实现的可供分配利润的一定比例向股东分配股利。同时，公司董事会应当综合考虑所处行业特点、 发展阶段、自身经营模式、盈利水平、债务偿还能力、是否有重大资金支出安排和投资者回报等因素， 提出差异化的现金分红政策。现金分红在本次利润分配中所占比例最低应当达到百分之二十。 ...

会议资料 二○二五年五月 山鹰国际 600567 2024 年年度股东会会议资料 山鹰国际 600567 2024 年年度股东会会议资料 山鹰国际控股股份公司 目 录 议案六、关于确认公司董事 2024 年度薪酬发放情况及 2025 年度薪酬 议案七、关于确认公司监事 2024 年度薪酬发放情况及 2025 年度薪酬 议案九、关于 2025 年度向金融机构申请综合授信额度的议案 ... 33 议案十一、关于公司及控股子公司提供资产抵押的议案 ........ 38 议案十二、关于公司及控股子公司开展金融衍生品投资业务的议案 第 2页 共 46 页 山鹰国际 600567 2024 年年度股东会会议资料 议案十三、关于制定《山鹰国际控股股份公司未来三年 （2025-2027） 第 3 页 共 46 页 山鹰国际 600567 2024 年年度股东会会议资料 会议议程 会议时间：2025 年 5 月 21 日 14:30 会议方式：现场投票和网络投票相结合 现场会议地点：安徽省马鞍山市勤俭路山鹰国际办公大楼 会议主持人：吴明武先生 一、主持人宣布会议开始，公布参加股东会股东人数及所代表的 有表决权股份数； 二、会 ...

Core Viewpoint - The company, Hao Xiang Ni, reported a revenue of 1.67 billion yuan in 2024, a year-on-year decrease of 3.39%, and a net profit attributable to shareholders of -72 million yuan, a decline of 38.67%, marking three consecutive years of losses [1] Group 1: Financial Performance - In 2024, the company achieved a revenue of 1.67 billion yuan, down 3.39% year-on-year [1] - The net profit attributable to shareholders was -72 million yuan, representing a 38.67% decline compared to the previous year [1] - Cumulatively, the company has incurred losses exceeding 300 million yuan over the past three years, with net profits of -189 million yuan in 2021 and -52 million yuan in 2022 [1] Group 2: Dividend Policy - Despite consecutive losses, the company plans to distribute a cash dividend of 10 yuan per 10 shares, totaling approximately 432 million yuan for the 2024 fiscal year, along with an additional 173 million yuan in mid-year dividends, bringing the total to 605 million yuan [2] - The company's management stated that the dividend policy considers both investor demands and sustainable business operations, aiming to enhance shareholder returns and confidence [3] Group 3: Shareholding Structure - Approximately 30% of the high dividends are allocated to the founder's family, with the chairman holding 28.59% of the shares, and other family members holding a combined total of over 31% [4] - The chairman, Shi Jubin, and his family members are identified as acting in concert, indicating a significant influence over the company's decisions [4]

根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司证券 发行注册管理办法》等有关法律、法规及规范性文件的规定，经过对公司实际情 况及相关事项进行自查和论证，监事会认为公司各项条件符合现行法律、法规和 规范性文件中关于上市公司向特定对象发行股票的有关规定，具备本次向特定对 象发行股票的资格和条件。 证券代码：300266 证券简称：兴源环境 公告编号：2025-039 兴源环境科技股份有限公司 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 兴源环境科技股份有限公司（以下简称"公司"）第六届监事会第四次会议 于2025年5月12日以通讯方式召开。会议通知已经于2025年5月9日以电子邮件方 式送达全体监事。本次会议应出席监事3人，实际出席监事3人。本次会议的通知、 召开以及参会监事人数均符合相关法律、法规、规则及《公司章程》的有关规定。 本次会议形成以下决议： 一、审议通过《关于公司符合向特定对象发行股票条件的议案》 本议案尚需提交公司股东大会审议。 表决结果：同意3票，反对0票，弃权0票。 二、逐项审议通过《关于公司2025年度向特定对象发行A股股 ...

Core Viewpoint - Zhejiang Sitaili Pharmaceutical Co., Ltd. is preparing for its shareholder meeting scheduled for May 22, 2025, focusing on maintaining shareholder rights and ensuring orderly proceedings during the meeting [1][2]. Meeting Arrangements - The meeting will be held on May 22, 2025, at 14:30, with online voting available from 9:15 to 11:30 and 13:00 to 15:00 on the same day [3]. - The venue for the meeting is located at No. 9, Fengxi West Road, Modern Industrial Gathering Area, Xianju County, Zhejiang Province [3]. Shareholder Rights and Meeting Conduct - Shareholders have the right to speak, inquire, and vote, but must apply to the meeting's organizing committee to do so [2]. - The voting will be conducted via a named ballot, with each share granting one vote, and any improperly filled ballots will be considered as abstentions [2][3]. Board of Directors and Governance - The fifth board of directors consists of 7 members, including 3 independent directors, and has held 8 meetings during the reporting period to discuss various corporate matters [6]. - The board has focused on maintaining good governance and protecting shareholder interests through active discussions and independent opinions [6]. Financial Performance Overview - The company reported a steady growth in operating performance for 2024, with total assets reaching approximately 6.05 billion yuan, an increase of 9.59% compared to the previous year [15]. - The financial report indicates a decrease in cash and cash equivalents by 14.47% and a decline in accounts receivable by 10.76% [14][15]. Future Outlook - The company anticipates challenges in 2025 due to external factors such as safety and environmental risks, as well as increased competition in the industry [9]. - The board will closely monitor changes in external policies and economic conditions to provide strategic recommendations for sustainable development [9].

Meeting Information - The annual shareholders' meeting of Zhejiang Aoxiang Pharmaceutical Co., Ltd. is scheduled for May 20, 2025, at 14:00 [1] - The meeting will be held at the company's new office building in Linhai, Zhejiang [1] - Voting will be conducted through both on-site and online platforms [3] Shareholder Rights and Responsibilities - Shareholders must present identification and relevant documents to attend the meeting [2] - Shareholders have the right to speak, inquire, and vote during the meeting [2] - The meeting will follow a structured agenda, including the reading of proposals and voting on resolutions [2][3] Financial Performance - In 2024, the company reported a revenue of approximately RMB 795.29 million, a decrease of 2.63% from 2023 [18] - The net profit attributable to shareholders was approximately RMB 206.79 million, down 18.55% year-on-year [18] - The company's total assets increased by 1.04% to approximately RMB 2.98 billion, while net assets rose by 6.08% to approximately RMB 2.27 billion [18] Board of Directors' Report - The board emphasized a commitment to responsible governance and strategic decision-making to enhance shareholder value [4][6] - The board has established specialized committees to oversee various aspects of company operations, including audit and remuneration [6][7] Future Development Strategy - The company aims to leverage its R&D capabilities to capture opportunities in the global pharmaceutical market, particularly as many innovative drug patents expire [8] - The focus will be on developing high-value products and expanding into international markets [8][9] - The company plans to enhance its marketing strategies and strengthen customer relationships to ensure long-term growth [9] Profit Distribution Proposal - The board proposed a cash dividend of RMB 1 per 10 shares, totaling approximately RMB 82.83 million, which represents 40.05% of the net profit for 2024 [21]

Investment Rating - The investment rating for Rongsheng Petrochemical is "Buy" [1] Core Views - The company's performance has shown significant marginal improvement, and shareholder returns have enhanced its long-term investment value [1] - The report highlights that the refining and chemical industry is currently in a weak cycle, which may put short-term pressure on the company's performance [4] - The first quarter of 2025 saw a substantial improvement in the company's performance, indicating potential for profit elasticity [4][5] - The company has established a three-year shareholder return plan, emphasizing its long-term investment value [7] Financial Performance Summary - In 2024, the company achieved operating revenue of 326.475 billion yuan, a year-on-year increase of 0.42%, while net profit attributable to shareholders was 724 million yuan, a decrease of 37.44% [1] - The first quarter of 2025 reported operating revenue of 74.975 billion yuan, a year-on-year decrease of 7.54%, but net profit attributable to shareholders increased by 6.53% year-on-year [2] - The forecast for 2025-2027 indicates a significant recovery in net profit, with expected figures of 2.356 billion yuan, 2.783 billion yuan, and 3.935 billion yuan respectively, reflecting growth rates of 225.2%, 18.1%, and 41.4% [7] Industry Insights - The refining industry is entering a phase of stock competition, with a focus on "strong alliances" to create new development opportunities [4] - The average Brent crude oil price for 2024 is projected to be 79.86 USD/barrel, indicating a slight decrease from the previous year [4] - The report notes that the company is collaborating with Saudi Aramco, which is expected to enhance its global market presence and operational resilience [5]